• <tr id='Drm9au'><strong id='Drm9au'></strong><small id='Drm9au'></small><button id='Drm9au'></button><li id='Drm9au'><noscript id='Drm9au'><big id='Drm9au'></big><dt id='Drm9au'></dt></noscript></li></tr><ol id='Drm9au'><option id='Drm9au'><table id='Drm9au'><blockquote id='Drm9au'><tbody id='Drm9au'></tbody></blockquote></table></option></ol><u id='Drm9au'></u><kbd id='Drm9au'><kbd id='Drm9au'></kbd></kbd>

    <code id='Drm9au'><strong id='Drm9au'></strong></code>

    <fieldset id='Drm9au'></fieldset>
          <span id='Drm9au'></span>

              <ins id='Drm9au'></ins>
              <acronym id='Drm9au'><em id='Drm9au'></em><td id='Drm9au'><div id='Drm9au'></div></td></acronym><address id='Drm9au'><big id='Drm9au'><big id='Drm9au'></big><legend id='Drm9au'></legend></big></address>

              <i id='Drm9au'><div id='Drm9au'><ins id='Drm9au'></ins></div></i>
              <i id='Drm9au'></i>
            1. <dl id='Drm9au'></dl>
              1. <blockquote id='Drm9au'><q id='Drm9au'><noscript id='Drm9au'></noscript><dt id='Drm9au'></dt></q></blockquote><noframes id='Drm9au'><i id='Drm9au'></i>

                BCEIA2019 International Summit on Analytical Instrumentation and IVD

                2019年7月18日 16:37:30 來源: 中國分析測試協會

                BCEIA2019 International Summit on Analytical Instrumentation and In Vitro Diagnosis

                --Registration in Progress

                In recent years,In Vitro Diagnosis has become one of the fastest growing segments in the field of life sciences and clinical medicine worldwide. Statistics reveal that in 2018, the size of the global InVitro diagnosis market reached USD 80 billion while the Chinese market reached RMB 50 billion, representing an annual growth of 15%.

                The rapid growth in the Chinese InVitro diagnosis market is driven by China's large population, the substantial growth of the economy, great population mobility, the increase in emerging infectious diseases,enhancement of people's awareness about health and the Government's development initiatives regarding the healthcare industry and biotechnology industrialization.

                Market factors are driving the development of analytical sciences to focus more on InVitro diagnosis, and as a result, the usage of some analytical technologies such as mass spectrometers and digital PCR are experiencingincreasedusage in the early screening of cancer and nerve system diseases.

                Analytical technology and testing methods are developing at an everincreasing speed. Mass spectrometry platforms have become the spotlight of Clinical medical examination, especially in microorganismidentification, neonatal screening and identification of tumor markers. Electrochemiluminescence technology is a new testing technology based on immunological technique, antibody technology and biotechnology, which has gained extensive application in clinical detection thanks to its characteristics of high sensitivity, strong stability, good repeatability and a highdegreeofautomation.

                Small Molecule Testing has always been a strength of analytical technology but has been limited by various conditions of samples, and sample pre-treatment is always required. Based on the small molecule antibody technology and enzymology, Homogeneous Enzyme Immunoassay (HEIA) technology was developed to overcome the limitations on sample influences, and hence resolve the problem of mass clinical testing requirements. HEIA technology is well applied in tumors, metabolism and internal secretion diseases, and clinical sample testing has improved in terms efficiency and accuracy.

                The “International Summit on Analytical Instrumentation and InVitro Diagnosis” specially invites renowned interdisciplinary experts to participate in debates on the development and application of analytical instruments and technology in the field of InVitro diagnosis, and the perspective of human health. The Summit will be one of the highlight events of BCEIA 2019.

                International Summit on Analytical Instrumentation

                and In Vitro Diagnosis


                  Date: 23October, 2019 (09:30-12:45)

                  Location: InterContinental Beijing Beichen, China

                  Language: Chinese and English







                Opening Speech

                Huwei Liu
                  Peking University


                Overview Report-Technology Innvoation and Hospital Developmen

                Qimin Zhan
                  Academician of CAE
                  Peking University


                Single Cell Omics: Decoding Human Genome

                Xiaoliang Sunney Xie
                  Academician of NAS, United States
                  Peking University


                Electrochemiluminescence Immunoassay and Its Application

                Ying Zeng
                  Lifotronic Technology Co, Ltd


                Coffee Break


                Advancements in MS imaging for Biomedical Research

                Emmanuelle Claude
                  Principal Scientist
                Health Sciences Business
                  Waters Corporation


                Applications of Homogeneous Enzyme Immunoassay (HEIA) for Small   Molecule Testing

                Liuming Yu
                  Chairman& CEO
                  Suzhou Evermed Biomedical Co, Ltd


                Closing Speech

                Huwei Liu
                  Peking University

                  Guest Moderator


                Huwei Liu

                Huwei Liu is the Ph.D. Professor of Institute of Analytical Chemistry, College of Chemistry and Molecular Engineering, Peking University.

                Dr. Huwei Liu graduated with a BA degree in 1982, and Ph?D? in 1990 from Beijing Institute of Technology (BIT), China, then he joined Peking University, became a full professor in 2001. His research work focuses on bioseparation and detection, including fundamentals and applications of chromatographic, electrophoretic separation techniques and mass spectrometry, as well as hyphenated methods such as LC-MS and CE-MS. The application areas cover pharmaceutical analysis, plan hormone detection, proteomics and lipidomics analysis. He is the author and co-author of more than 280 research papers and reviews, 3 books, and several chapter contributions of the edited books. He is currently a member of Chinese Chemical Society and American Chemical Society, a vice president of China Mass Spectrometry Society, president of Beijing Chromatography Society. Reputy Secnetany General of China Association for Instrumental Analysis (CAIA). He also serves as an associate editor of Journal of Separation Science and Journal of Analysis and Testing, an executive editor of Chinese Journal of Chromatography, an advisory/editorial board member for Analytical Chemistry(2013-2015), Analytical and Bioanalytical Chemistry, Molecules (Section Board for 'Analytical Chemistry') and other ten Chinese journals.

                  Keynote Speakers


                Qimin Zhan, MD

                Qimin Zhan, MD, is currently an Academician of the Chinese Academy of Engineering, the Executive Vice President of Peking University, President of Peking University Health Science Center, President of Peking University Shenzhen Graduate School, and the Director of the State Key Laboratory of Molecular Oncology.

                Dr. Zhan is the chairman of National Health Care Project and the chairman of National Biotechnology Development Strategy. He was the Chairman of the National Advisory Board for 863 High-Tech plan in the field of biomedical sciences and is the Chief Scientist of the 973 National Fundamental Program. Dr. Zhan’s research interest is focused on the molecular pathways involved in the control of cell cycle checkpoint and apoptosis after DNA damage, and the signaling pathways involved in regulation of the maintenance of genomic stability and tumor metastasis. In recent years, Dr. Zhan has paid great attention to the cancer translational study, including molecular diagnosis and personalized therapy. His research has successfully attracted multiple grants from different funding agencies. Dr. Zhan’s has published more than 240 peer-reviewed SCI papers. Many of his publications are in prestigious journals, including Nature, Cell, the Journal of Clinical Investigation, and others. To date, they have been cited more than 14,000 times.


                Xiaoliang Xie

                Professor Xie is an internationally renowned biophysical chemist, and the Lee Shao-kee professor of Peking University. After a career at Pacific Northwest National Laboratory, he became the first tenured professor at Harvard University among Chinese scholars who went to the US since the Reform in China. As a pioneer of single-molecule biophysical chemistry, coherent Raman scattering microscopy, and single-cell genomics, he made major contributions to the emergence of these fields. In particular, his inventions in single-cell genomics have been used in in vitro fertilization to benefit hundreds of couples in China by avoiding the transmission of monogenic diseases to their newborns.


                Ying Zeng

                Mr. Zeng is the EVP of Lifotronic Technology Co., Ltd., who is in charge of the Research and Develop Department of the company.

                IVD Division of Lifotronic has developed an electrochemiluminescence immunoassay system, a nephelometer immunoassay system, a lateral flow immunofluorescence analysis system, a HPLC HbA1c analysis system and a thrombelastogram analysis system. The nephelometer immunoassay system has won the first prize of the progress of science and technology in Shenzhen.

                Healing products Division of Lifotronic developed wound treatment solutions, have won the first prize of the national award of the progress of science and technology.

                Mr. Zeng has also worked in GE Healthcare,China and Shenzhen Mindray Biomedical Electronics Co., Ltd for nearly 20 years.